The World Health Organization has highlighted a single-dose HPV vaccination schedule for girls aged nine to 14 as a way to expand protection. Its departmental update on 29 October reports the conclusions of an expert review held earlier this month.
The gap remains substantial: 165 countries have introduced HPV vaccination, but global coverage was 33% in 2025, far below the 90% target. The figures show why introducing a vaccine and actually reaching the intended population are different achievements.
This is not the discovery of a new vaccine or the first recommendation for a one-dose schedule. WHO had already included single-dose options in its 2022 policy. The latest message puts the emphasis on reaching more people with available programme resources.
HPV vaccination is part of cervical cancer prevention. A simpler schedule can reduce the number of return visits needed, but an appointment still has to be offered, explained and made accessible. Supply, outreach and trust remain part of the same task.
The programme-level message should not be mistaken for an instruction to change an individual’s prescribed schedule. WHO’s existing guidance includes additional doses for people with weakened immune systems, including those living with HIV. National recommendations and the applicable product guidance also matter.
The public-health test is therefore practical: can a simpler approach close the gap between a vaccine being available and a girl receiving protection? The October update renews that focus without removing the need for clear clinical and national guidance.
